SCHEMBL23928131

SCHEMBL23928131

CC(C)(C)OC(=O)NCCc1ccc(NC2CCS(=O)(=O)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.51
CA2 P00918 3/20 0.47
CA1 P00915 2/20 0.47
IGF1R P08069 1/20 0.46
SIGMAR1 Q99720 3/20 0.42
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX1 P07099 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
PTGER4 P35408 1/20 0.39
FPR3 P25089 2/20 0.39
FPR2 P25090 2/20 0.39
ROCK2 O75116 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928128 0.91 NAMPT (0.51) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL23928179 0.85 NAMPT (0.52) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL7090774 0.85 NAMPT (0.52) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL23928203 0.85 NAMPT (0.52) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL23291152 0.82 NAMPT (0.54) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL23928178 0.82 NPC1 (0.42) ALDH1A1NPC1RAB9AL3MBTL1EPHX1
SCHEMBL23291278 0.81 NAMPT (0.50) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL30479478 0.79 NAMPT (0.59) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL29033601 0.79 NAMPT (0.59) NAMPTCA2CA1IGF1RSIGMAR1
SCHEMBL7091709 0.77 ADRB3 (0.59) NAMPTCA2CA1SIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 NAMPT 1862/4885CA2 2300/4885CA1 1788/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 NAMPT 1862/4885CA2 2300/4885CA1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.